Southeastern Printing, a premier South Florida omni-channel marketing and brand management company, announces its achievement ...

Neurotone AI, pioneer in aural rehabilitation, and creator of Lace AI Pro, today announced it has entered into a definitive agreement to acquire Amptify, a leading digital hearing healthcare platform ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust ...

Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol at ...

As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25% of ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update NeuroBo Becomes MetaVia On November 18, 2024, NeuroBo Pharmaceuticals ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.